Journal for ImmunoTherapy of Cancer. 2025; 13(4); 10.1136/jitc-2024-010736
Journal of Controlled Release. 2025; 381(May 10); 113645
Overcoming P-glycoprotein-mediated multidrug resistance in cancer cells through micelle-forming PHPMA-b-PPO diblock copolymers for doxorubicin delivery
ACS Applied Bio Materials. 2025; 8(1); 271-284
Dual thermo- and pH-responsive polymer nanoparticle assemblies for potential stimuli-controlled drug delivery
Clinical Cancer Research. 2025; 31(1); 164-180
Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
JCI Insight. 2024; 9(18); e173469
Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity
Block copolymer for overcoming drug resistance of tumours to chemotherapy; its polymer-drug conjugate; pharmaceutical composition containing them; method of preparation and use thereof
Nanomedicine: Nanotechnology; Biology and Medicine. 2024; 56(February 2024); 102730
Chemosensitization of tumors via simultaneous delivery of STAT3 inhibitor and doxorubicin through HPMA copolymer-based nanotherapeutics with pH-sensitive activation.
Nature Communications. 2024; 15(1); 2528
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Journal of Controlled Release. 2023; 353(January); 549-562
Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models
eLife. 2023; 12(Jan 27); e79342